Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (13132)	9/27/2004 9:46:30 AM
From: scaram(o)uche	Respond to of 52153

Ballroom A just playing music. Don't know if it's technical difficulty, or if the Myogen presentation was pulled from webcast.

To: Icebrg who wrote (13132)	9/27/2004 9:49:35 AM
From: Icebrg	Read Replies (1) \| Respond to of 52153

ABGX @ UBS The company's new CEO Mr. Ringo managed his "presentation" in a mere 15 minutes. So, now we know why his predecessor Withy was always talking so extremely slowly. There simply isn't much to tell about this company. There were - as far as I could tell - no new news during the presentation. Well, there should be some "results" from the stage I, single dose trial for ABX-PTH coming out at a conference next week. But that will hardly be something moving the share price. And ABX-MA1 will be offered to AZN for a look under the collaboration agreement. Apart from that - nothing. Maybe a little bit more than the normal dash of criticism directed towards Withy for having mismanaged the company. Already after four weeks "in control" Ringo claims to know what has to be done to improve the company's overall efficiency. Given of course that Abgenix has put itself in a very tight spot. Their most advanced product is under tight control by Amgen. Their broad anti-cancer efforts are controlled by Astra-Zeneca. And their very expensive production facility appears to be idling. Erik